---

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of September 2016

Commission File Number: 001-36621

FOAMIX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

2 Holzman Street, Weizmann Science Park

Rehovot, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

CONTENTS

Foamix Pharmaceuticals Ltd. (the "Company") is planning to participate and present at the Rodman & Ranshaw Annual Global Investment Conference, on September 12, 2016. In preparation for these events, the Company has updated its investors' presentation, a copy of which is attached as Exhibit 99.1.

 

EXHIBITS

 

Exhibit 99.1:          Foamix Pharmaceuticals Ltd. Investors Presentation

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	FOAMIX PHARMACEUTICALS LTD.
Date: September 12 , 2016	By:	/s/ Ilan Hadar
		Name: Ilan Hadar
		Title: Chief Financial Officer

 

2

---